John J. Reddington
Directeur/Bestuurslid bij 3Brain AG
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Anthony N. Thompson | M | 56 |
Grid News Bureau LLC
| - |
| Marco Ferrato | M | - |
3Brain AG
 3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | - |
| Aris Persidis | M | - |
Grid News Bureau LLC
| - |
| Bruno Odermatt | M | - |
3Brain AG
3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | - |
| Laura Maness | F | - |
Grid News Bureau LLC
| - |
| Mauro Gandolfo | M | - |
3Brain AG
3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | - |
| Tom Deisboeck | M | - |
Grid News Bureau LLC
| - |
| Len Schutzman | M | - |
Grid News Bureau LLC
| - |
| Mary Daily | F | - |
Grid News Bureau LLC
| - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Joseph A. Markey | M | - |
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | - |
| Mark McDade | M | 69 |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 6 jaar |
| Gregory M. McKee | M | 60 |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 3 jaar |
| Lee B. Bussey | M | - |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | 12 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 10 | 76.92% |
| Zwitserland | 3 | 23.08% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- John J. Reddington
- Persoonlijk netwerk
